Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.59 |
| ▸ | POLA1 | P09884 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668294 | 0.90 | POLA1 (0.59) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6670482 | 0.89 | KCNH2 (0.59) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6698352 | 0.88 | F2 (0.62) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6668954 | 0.88 | KCNH2 (0.57) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6667353 | 0.88 | POLA1 (0.57) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6704417 | 0.87 | F2 (0.65) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6696146 | 0.86 | F2 (0.61) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6702138 | 0.86 | F2 (0.59) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL30372497 | 0.86 | MEN1 (0.73) | F2KCNH2POLA1MEN1KMT2A | |
| SCHEMBL6699690 | 0.86 | MEN1 (0.73) | F2KCNH2POLA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | claimed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | claimed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | disclosed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | F2 555/4885KCNH2 4383/4885POLA1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.